Cargando…

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers

Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene can cause late-onset Parkinson disease (PD). LRRK2 mutations increase LRRK2 kinase activities that may increase levels of LRRK2 autophosphorylation at serine 1292 (pS1292) and neurotoxicity in model systems. pS1292-LRRK2 protein can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shijie, Liu, Zhiyong, Ye, Tao, Mabrouk, Omar S., Maltbie, Tyler, Aasly, Jan, West, Andrew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700679/ https://www.ncbi.nlm.nih.gov/pubmed/29166931 http://dx.doi.org/10.1186/s40478-017-0492-y

Ejemplares similares

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
por: Warø, Bjørg Johanne, et al.
Publicado: (2017)

Exosome markers of LRRK2 kinase inhibition
por: Wang, Shijie, et al.
Publicado: (2020)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort
por: Aasly, Jan O.
Publicado: (2021)

Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers
por: Ouzren, Nassima, et al.
Publicado: (2019)

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
por: Zhao, Ye, et al.
Publicado: (2018)

Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers
por: Pont-Sunyer, Claustre, et al.
Publicado: (2015)

Novel recruitment strategy to enrich for LRRK2 mutation carriers
por: Foroud, Tatiana, et al.
Publicado: (2015)

Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity
por: Kluss, Jillian H., et al.
Publicado: (2018)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

Dynamic and redundant regulation of LRRK2 and LRRK1 expression
por: Biskup, Saskia, et al.
Publicado: (2007)

Parkin Exon Rearrangements and Sequence Variants in LRRK2 Mutations Carriers: Analysis on a Possible Modifier Effect on LRRK2 Penetrance
por: Solla, Paolo, et al.
Publicado: (2010)

α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers
por: Gorostidi, Ana, et al.
Publicado: (2012)

Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
por: Gersel Stokholm, Morten, et al.
Publicado: (2020)

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status
por: Reynolds, April, et al.
Publicado: (2014)

Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
por: Gomes, Sara, et al.
Publicado: (2023)

What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?
por: Loeffler, David A., et al.
Publicado: (2019)

Generalized dystonia without Parkinsonism in an LRRK2 carrier
por: Díaz-Feliz, Lola, et al.
Publicado: (2022)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation
por: Kumar, Azad, et al.
Publicado: (2010)

Metabolomic Profiling in LRRK2-Related Parkinson's Disease
por: Johansen, Krisztina K., et al.
Publicado: (2009)

Mitochondrial Mechanisms of LRRK2 G2019S Penetrance
por: Delcambre, Sylvie, et al.
Publicado: (2020)

Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021)

Capturing the domain crosstalk in full length LRRK2 and LRRK2(RCKW)
por: Störmer, Eliza, et al.
Publicado: (2023)

Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?
por: Saunders-Pullman, Rachel, et al.
Publicado: (2014)

Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
por: Droby, Amgad, et al.
Publicado: (2022)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
por: Kelly, Kaela, et al.
Publicado: (2020)

Differential LRRK2 signalling and gene expression in WT-LRRK2 and G2019S-LRRK2 mouse microglia treated with zymosan and MLi2
por: Nazish, Iqra, et al.
Publicado: (2023)

Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
por: De Wit, T., et al.
Publicado: (2018)

Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling
por: Berwick, Daniel C., et al.
Publicado: (2017)

A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2
por: Kuhlmann, Naila, et al.
Publicado: (2020)

The LRRK2 signalling system
por: Price, Alice, et al.
Publicado: (2018)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Increased Phospho‐AKT in Blood Cells from LRRK2 G2019S Mutation Carriers
por: Garrido, Alicia, et al.
Publicado: (2022)

LRRK2 dephosphorylation increases its ubiquitination
por: Zhao, Jing, et al.
Publicado: (2015)

Serotonin transporter binding and motor onset of Parkinson's disease in asymptomatic LRRK2 mutation carriers: a cross-sectional study
por: Wile, Daryl J, et al.
Publicado: (2017)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out
por: MacIsaac, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4n5ed27u2s5gkteht706qs06d